Interim Report January – June 2017
April – June 2017 in brief · Order intake increased by 1.1% to SEK 7,539 M (7,460). The order intake declined organically by 3.8%. · Net sales rose by 4.5% to SEK 7,241 M (6,927). Net sales decreased organically by 0.5%. · Cash flow from operations declined 51.8% to SEK 223 M (463). The cash conversion amounted to 29.1% (44.7). · EBITA 1* increased 9.6% to SEK 864 M (788). · Restructuring and integration costs amounted to SEK 524 M (133), of which SEK 488 M comprised a provision for improvements in Hechingen in accordance with the Consent Decree with the FDA. ·